Home > News > Latest > Novir Announces the Evolution of Their Business to a More Comprehensive Healthcare Solutions Provider Focused on Advancing the Pre-Care Pathway

MedTech

Novir Announces the Evolution of Their Business to a More Comprehensive Healthcare Solutions Provider Focused on Advancing the Pre-Care Pathway

Novir, an emerging biotechnology company, focused on pioneering the pre-care pathway to better health, has announced today the launch of their refreshed brand, dedicated to showcasing the evolution Novir has taken from a COVID-19 testing and vaccination provider to a more comprehensive healthcare solution committed to advancing healthcare from sick-care to pre-care by offering affordable, accessible, and reliable screening solutions to anyone, anywhere, anytime.

Since their inception in 2020 amidst the pandemic, Novir worked to provide over 600,000 life-saving screenings or vaccinations across the US. Now, Novir has evolved to an international organization with a vision of providing an expanded portfolio of healthcare solutions that are more accessible, affordable, and reliable for everyone regardless of background, location, or other demographic characteristics; all supported by Novir’s proprietary technology platform that brings simplicity to a new, accessible healthcare service delivery model.

"Preventive healthcare is more important than ever, and we are excited to launch our new Novir platform to help our customers take control of their own health and get the proper care they need, ideally before symptoms arise," said Alexander Kempe, President, and CEO. "Our team has worked tirelessly to create an easy-to-use platform that provides the latest information and resources to help prevent illnesses and promote health."

Novir’s new website offers a wide range of information and resources about their customers served as well as Novir’s comprehensive healthcare solutions portfolio including

Onsite health solutions, delivering screenings and vaccinations directly to senior living communities and schools Virtual drug testing services to employers and rehabilitation centers Preventive health solutions offered to employees and other organizations Products focused on preventive care for rapid detection in-home and at the point of care

About Novir

Novir is a cutting-edge biotechnology company revolutionizing the way the world perceives and approaches healthcare. At Novir, we challenge the conventional care model by placing our focus on proactive measures rather than waiting for diagnoses. We firmly believe that care shouldn't start at diagnosis, but rather in the early stages of prevention. Our mission is to empower individuals to take charge of their health through innovative services and technologies that enable a pre-care pathway for anyone, anywhere, anytime, connecting you to the standard of care.

Spotlight

Other News

Medical

Personalis and ClearNote Health Announce Partnership to Advance Epigenomic Technology

Personalis, Inc. | February 05, 2024

Personalis, Inc. a leader in advanced genomics for cancer, and ClearNote Health, Inc., a pioneer in epigenomic technologies, today unveiled an alliance through which Personalis will expand its pharmaceutical service offerings by distributing ClearNote’s cutting-edge epigenomic 5-hydroxymethylcytosine (5hmC) platform. “We have built a unique pharma channel based on our industry-leading tissue and MRD assays and ClearNote Health’s blood-based epigenomic approach is complementary to our offering as it helps our customers deepen their understanding of a patient’s response to immunotherapies,” said Chris Hall, CEO and President of Personalis. “Commercial partnerships such as this broaden our portfolio and are expected to appeal to a wide range of biopharma customers and accelerate our revenue growth.” Echoing this sentiment, Dave Mullarkey, CEO of ClearNote Health, remarked, “Partnering with Personalis presents an excellent opportunity to bring our 5hmC technology to the forefront of cancer research. This alliance is a testament to the synergy between our two companies, enabling us to expand our reach and significantly impact the biopharmaceutical industry. Together, we can accelerate the development of personalized therapies and make a real difference in the lives of patients.” ClearNote Health’s Epigenomics Platform represents a groundbreaking advance in cancer detection, offering real-time insights into disease-specific pathways. By tracking changes in 5hmC levels coupled with artificial intelligence-based analytical methods, the platform can detect cancer earlier, monitor disease progression, understand mechanisms of resistance, and identify promising drug targets and biomarkers. These insights are invaluable for optimizing drug development programs and delivering more effective treatments to patients. The Epigenomics Platform identifies changes in gene activation and gene regulation by labeling specific changes in the 5hmC landscape from plasma-derived cell-free DNA. This rich biological information, as part of clinical trials, enables the monitoring of cancer therapies in real time and contributes to an understanding of drug resistance mechanisms. The partnership marks a pivotal moment in cancer research, leveraging the strengths of both companies to offer unparalleled solutions in the biopharmaceutical industry. About ClearNote Heath, Inc. ClearNote Health is a cancer detection company focused on enabling people at risk for high-mortality cancers to live longer, healthier lives. Utilizing a standard blood draw, the company applies its proprietary epigenomic platform, combining biology and artificial intelligence, to identify DNA-based changes in biology as cancer develops. With lead programs in non-invasive early detection of pancreatic and ovarian cancers in patients at the highest risk for these diseases, ClearNote Health identifies cancers before they progress and when patients are most likely to benefit from treatment. ClearNote Health’s first commercially available test is the Avantect™ Pancreatic Cancer Test, which detects the presence of pancreatic cancer signals in patients at high risk of the disease, including those recently diagnosed with Type 2 diabetes. ClearNote Health is headquartered in San Diego, with additional presence in the San Francisco Bay area and internationally. The company’s CLIA- and CAP-accredited laboratory is located in San Diego, Calif. About Personalis, Inc. At Personalis, we are transforming the active management of cancer through breakthrough personalized testing. We aim to drive a new paradigm for cancer management, guiding care from biopsy through the life of the patient. Our highly sensitive assays combine tumor-and-normal profiling with proprietary algorithms to deliver advanced insights even as cancer evolves over time. Our products are designed to detect minimal residual disease (MRD) and recurrence at the earliest time points, enable the selection of targeted therapies based on ultra-comprehensive genomic profiling, and enhance biomarker strategy for drug development. Personalis is based in Fremont, California.